Electromed, Inc. (NYSE:ELMD) Shares Bought by Navellier & Associates Inc.

Navellier & Associates Inc. raised its stake in Electromed, Inc. (NYSE:ELMD) by 228.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 56,368 shares of the company’s stock after purchasing an additional 39,208 shares during the period. Navellier & Associates Inc.’s holdings in Electromed were worth $1,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ELMD. Ritholtz Wealth Management acquired a new stake in shares of Electromed during the fourth quarter worth about $488,000. Barclays PLC acquired a new stake in shares of Electromed during the third quarter worth about $215,000. State Street Corp boosted its stake in shares of Electromed by 14.5% during the third quarter. State Street Corp now owns 22,066 shares of the company’s stock worth $474,000 after buying an additional 2,800 shares during the period. Walleye Capital LLC acquired a new stake in shares of Electromed during the third quarter worth about $274,000. Finally, Legacy Wealth Asset Management LLC acquired a new stake in shares of Electromed during the fourth quarter worth about $253,000. Institutional investors and hedge funds own 40.82% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ELMD shares. StockNews.com downgraded shares of Electromed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. B. Riley started coverage on shares of Electromed in a research note on Thursday. They set a “buy” rating and a $38.00 target price for the company.

Insider Buying and Selling

In related news, Director Andrew Summers sold 17,463 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $30.09, for a total transaction of $525,461.67. Following the completion of the transaction, the director now directly owns 189,838 shares of the company’s stock, valued at $5,712,225.42. This represents a 8.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Kathleen Skarvan sold 38,954 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the transaction, the director now directly owns 32,622 shares of the company’s stock, valued at $955,172.16. This represents a 54.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 77,788 shares of company stock valued at $2,326,350 over the last ninety days. Corporate insiders own 14.00% of the company’s stock.

Electromed Stock Down 2.3 %

NYSE ELMD opened at $27.97 on Friday. The stock has a market capitalization of $239.42 million, a P/E ratio of 37.29 and a beta of 0.33. Electromed, Inc. has a 52-week low of $13.74 and a 52-week high of $35.56. The firm has a 50-day moving average price of $31.40 and a 200 day moving average price of $25.26.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.